Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

JP Morgan Cuts Endo Pharma to 'Long-term Buy'

JP Morgan downgraded Endo Pharma (ENDP) to long term buy from buy.

Analyst Corey Davis says his downgrade is based on his view that the current 23% premium to its peers already reflects the positive outcome for the company's latest drug, Morphidex, a treatment for cancer pain. He thinks Morphidex has a 75% chance for a positive outcome in the June Phase III trials, however, he notes recent market has been unrelenting in its punishment for failure. Davis sees $0.41 2002 earnings per share; he says would cut his $0.46 2003 estimate to $0.35 if Morphidex is not approved. He believes, if Morphidex does not hit its primary endpoint in June, the potential downside to the stock price far outweighs the upside from a positive earnings outcome. Davis has a $15 target.

blog comments powered by Disqus